Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Discovery Today

• Publication date

  2011-05-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.drudis.2011.02.012PMID 21354326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Principles of early drug discovery

  2011cited by this paper
• Three-Dimensional Culture of Human Embryonic Stem Cell Derived Hepatic Endoderm and Its Role in Bioartificial Liver Construction

  2010cited by this paper
• Induced pluripotent stem cells: a new era for hepatology.

  2010cited by this paper
• Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites

  2010cited by this paper
• Lidocaine/monoethylglycinexylidide test, galactose elimination test, and sorbitol elimination test for metabolic assessment of liver cell bioreactors.

  2010cited by this paper
• State-of-the-art management and monitoring of brain edema and intracranial hypertension in fulminant hepatic failure. A proposed algorithm.

  2010cited by this paper
• How Our Growing Understanding of Inflammation Has Reshaped the Way We Think of Disease and Drug Development

  2010cited by this paper
• Hepatogenesis of Adipose-Derived Stem Cells on Poly-Lactide-co-Glycolide Scaffolds: In Vitro and In Vivo Studies

  2010cited by this paper
• Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development

  2010cited by this paper
• Transdifferentiation of adipose‐derived stem cells into hepatocytes: a new approach

  2010cited by this paper
• The Comparison between Conditioned Media and Serum-Free Media in Human Embryonic Stem Cell Culture and Differentiation

  2010cited by this paper
• Human stem cells and drug screening: opportunities and challenges

  2010cited by this paper
• Transcriptional Profiling of Human Embryonic Stem Cells Differentiating to Definitive and Primitive Endoderm and Further Toward the Hepatic Lineage

  2010cited by this paper
• Factors from Human Embryonic Stem Cell-derived Fibroblast-like Cells Promote Topology-dependent Hepatic Differentiation in Primate Embryonic and Induced Pluripotent Stem Cells*

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• An In Vitro Assay to Assess Transporter-Based Cholestatic Hepatotoxicity Using Sandwich-Cultured Rat Hepatocytes

  2010cited by this paper
• Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats

  2010cited by this paper
• Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages

  2010cited by this paper
• CYP-Mediated Therapeutic Protein-Drug Interactions

  2010cited by this paper
• Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening.

  2010cited by this paper
• In vitro hepatic maturation of human embryonic stem cells by using a mesenchymal cell line derived from murine fetal livers

  2010cited by this paper
• Telomerase activity and hepatic functions of rat embryonic liver progenitor cell in nanoscaffold-coated model bioreactor

  2010cited by this paper
• From skin cells to hepatocytes: advances in application of iPS cell technology.

  2010cited by this paper
• Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.

  2010cited by this paper
• Highly efficient generation of human hepatocyte–like cells from induced pluripotent stem cells

  2010cited by this paper
• Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.

  2010cited by this paper
• Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.

  2010cited by this paper
• Hepatoblast-like progenitor cells derived from embryonic stem cells can repopulate livers of mice.

  2010cited by this paper
• Preclinical characterization of primary porcine hepatocytes in a clinically relevant flat membrane bioreactor.

  2010cited by this paper
• Inflammation: Planning for a Source of Pharmacokinetic/Pharmacodynamic Variability in Translational Studies

  2010cited by this paper
• Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage.

  2010cited by this paper
• Generation of endoderm‐derived human induced pluripotent stem cells from primary hepatocytes

  2010cited by this paper
• Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity

  2010cited by this paper
• Differentiated human adipose‐derived stem cells exhibit hepatogenic capability in vitro and in vivo

  2010cited by this paper
• Metabolites in Safety Testing: “MIST” for the Clinical Pharmacologist

  2010cited by this paper
• Therapeutic Protein–Drug Interactions and Implications for Drug Development

  2010cited by this paper
• Evaluation of 99mTechnetium-Mebrofenin and 99mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human Hepatocytes

  2010cited by this paper
• Differentiation and Characterization of Metabolically Functioning Hepatocytes from Human Embryonic Stem Cells

  2010cited by this paper
• Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells

  2009cited by this paper
• Stem cells in gastroenterology and hepatology

  2009cited by this paper
• Sequential Hepatogenic Transdifferentiation of Adipose Tissue-Derived Stem Cells: Relevance of Different Extracellular Signaling Molecules, Transcription Factors Involved, and Expression of New Key Marker Genes

  2009cited by this paper
• Future of bioartificial liver support.

  2009cited by this paper
• Generation of functional human hepatic endoderm from human induced pluripotent stem cells

  2009cited by this paper
• Progress and future challenges in stem cell-derived liver technologies.

  2009cited by this paper
• Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance

  2009cited by this paper
• Differentiation and transplantation of human embryonic stem cell-derived hepatocytes.

  2009cited by this paper
• Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?

  2009cited by this paper
• Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma.

  2009cited by this paper
• Properties of Hepatocyte-like Cell Clusters from Human Adipose Tissue-Derived Mesenchymal Stem Cells

  2009cited by this paper
• Hepatic differentiation of pluripotent stem cells

  2009cited by this paper
• 2D and 3D cell microarrays in pharmacology.

  2009cited by this paper
• Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

  2009cited by this paper
• Human embryonic stem cell technologies and drug discovery

  2009cited by this paper
• Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells

  2009cited by this paper
• Two compartment model of diazepam biotransformation in an organotypical culture of primary human hepatocytes.

  2009cited by this paper
• Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

  2009cited by this paper
• Expression of liver‐specific markers in naïve adipose‐derived mesenchymal stem cells

  2009cited by this paper
• Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice

  2008cited by this paper
• Human N-acetyltransferases and drug-induced hepatotoxicity.

  2008cited by this paper
• Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy

  2008cited by this paper
• Stem cells and drug discovery: the beginning of a new era?

  2008cited by this paper
• Aggravation of viral hepatitis by platelet-derived serotonin

  2008cited by this paper
• Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells

  2008cited by this paper
• Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling

  2008cited by this paper
• HLA-haplotype banking and iPS cells

  2008cited by this paper
• Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo

  2008cited by this paper
• Prediction of human pharmacokinetics—biliary and intestinal clearance and enterohepatic circulation

  2008cited by this paper
• Cellular imaging predictions of clinical drug-induced liver injury.

  2008cited by this paper
• Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.

  2008cited by this paper
• Age-related changes in the hepatic microcirculation in mice.

  2007cited by this paper
• Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells.

  2007cited by this paper
• Directed differentiation of human embryonic stem cells into functional hepatic cells

  2007cited by this paper
• The third dimension bridges the gap between cell culture and live tissue

  2007cited by this paper
• Human mesenchymal stem cells from adipose tissue: Differentiation into hepatic lineage.

  2007cited by this paper
• Adipose tissue‐derived mesenchymal stem cells as a source of human hepatocytes

  2007cited by this paper
• Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells.

  2007cited by this paper
• Designing synthetic materials to control stem cell phenotype.

  2007cited by this paper
• Regulation of drug transporters during infection and inflammation.

  2007cited by this paper
• Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies

  2007cited by this paper
• A novel formulation of oxygen‐carrying matrix enhances liver‐specific function of cultured hepatocytes

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Human Embryonic Stem Cell-Derived Cardiomyocytes Can Be Maintained in Defined Medium without Serum

  2006cited by this paper
• Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro.

  2006cited by this paper
• Metabolites and safety: What are the concerns, and how should we address them?

  2006cited by this paper
• Drug metabolism and variability among patients in drug response.

  2005cited by this paper
• PuraMatrix: Self-Assembling Peptide Nanofiber Scaffolds

  2005cited by this paper
• Technology Insight: liver support systems

  2005cited by this paper
• Mechanism of action of interferon and ribavirin in treatment of hepatitis C

  2005cited by this paper
• Scaffolding In Tissue Engineering

  2005cited by this paper
• Idiosyncratic drug hepatotoxicity

  2005cited by this paper
• Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching.

  2005cited by this paper
• A bioartificial liver support system using primary hepatocytes: a preclinical study in a new porcine hepatectomy model.

  2004cited by this paper
• Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.

  2004cited by this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cited by this paper
• Embryonic stem cells in drug discovery

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Liver regeneration: from myth to mechanism

  2004cited by this paper
• Aging Biology and Geriatric Clinical Pharmacology

  2004cited by this paper
• Active drug metabolites in drug development.

  2003cited by this paper
• Hepatocellular damage from non-steroidal anti-inflammatory drugs.

  2003cited by this paper

• Underestimation of glyphosate intake by the methods currently used by regulatory agencies

  2023cites this paper
• Answer to “Comments on ‘Quantifiable urine glyphosate levels detected in 99% of the French population, with higher values in men, in younger people, and in farmers’”

  2022cites this paper
• Improved Metabolic Pathways of Glycolysis, Glycogen Synthesis, the Urea Cycle, and Cytochrome Peroxidase Oxidative Reabsorption in a Miniature Bioreactor.

  2022cites this paper
• Optimizing culture conditions for hepatic differentiation of human inducedpluripotent stem cells: from 3D culture systems to co-cultures

  2018cites this paper
• Human Stakeholders and the Use of Animals in Drug Development

  2018cites this paper
• The Cell‐Surface N‐Glycome of Human Embryonic Stem Cells and Differentiated Hepatic Cells thereof

  2017cites this paper
• Hepatic Differentiation of Human Induced Pluripotent Stem Cells in a Perfused Three-Dimensional Multicompartment Bioreactor

  2016cites this paper
• Letter to the Editor

  2014cites this paper
• The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models

  2014cites this paper
• Implications of Differential Stress Response Activation Following Non-Frozen Hepatocellular Storage

  2013cites this paper
• Nanostructured self-assembling peptides as a defined extracellular matrix for long-term functional maintenance of primary hepatocytes in a bioartificial liver modular device

  2013cites this paper
• A Review of the Institute of Medicine’s Analysis of using Chimpanzees in Biomedical Research

  2013cites this paper
• Systematic Reviews of Animal Models: Methodology versus Epistemology

  2013cites this paper
• New Insights into Toxicity and Drug Testing

  2013cites this paper
• Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure

  2013cites this paper
• Animal Models in Drug Development

  2013cites this paper
• Animal models and conserved processes

  2012cites this paper
• Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model

  2012influential citation
• The Nuremberg Code subverts human health and safety by requiring animal modeling

  2012cites this paper
• Patients are not rodents writ large.

  2011cites this paper
• An analysis of the Bateson Review of research using nonhuman primates

  2011cites this paper
• Properties of Hepatocyte-like Cell Clusters from Human Adipose Tissue-Derived Mesenchymal Stem Cells

  2009cites this paper